A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors

Inclusion Criteria: Patients must meet all the following inclusion criteria to be eligible for enrollment into the study: 1. Histologically or cytologically-documented solid tumors that are inoperable locally advanced, metastatic, or recurrent: * Part 1 Dose Escalation: Patients with any solid tumor who have progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy. * Part 2: Dose Expansion: Patients must have received at least one prior line of standard therapy in recurrent/metastatic setting and for whom standard…